Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Colorado, Denver
Patients who have been taking Xalatan monotherapy to treat their glaucoma and presenting with ocular surface disease will be advised to switch their medication to Travatan Z. Test results will be recorded at the day that the medication was changed and at follow-up to determine if there is a measurable change in tear film break up, corneal staining and in the Ocular Surface Disease Index.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
on Xalatan monotherapy from 1 to 18 months
18 years of age or older
has been diagnosed with ocular surface disease
You may not be if
special populations such as children, pregnant females, prisoners, etc.
